BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.